Dr. Meenatai Naik

Dr. Meenatai Naik

Qualification:  MBBS,DNB (Radiation Oncology ),F-ESMO
Specialities : Radiation Oncology
Locations :  HCG Cancer Center – KR BLR, HCG Cancer Center – DR BLR

Introduction

Dr. Meenatai Venkatrao Naik is an experienced pathologist with a specialization in Oncopathology. With a strong background in working at leading cancer hospitals in India, as well as in resource-limited government hospitals, Dr. Naik has honed her skills both in collaborative team settings and independently. Her professional interests extend to academic activities and research, particularly in the field of cancer diagnostics. She is passionate about advancing knowledge in Oncopathology, as demonstrated by her research contributions. Notably, her work on “GATA-3 Expression in All Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma” was published in the Indian Journal of Surgical Oncology (2020), and her paper on the “Utility of GATA-3 in the Differential Diagnosis of Poorly Differentiated Urothelial Carcinoma” was accepted by the Journal of Cancer Research and Therapeutics in 2022.

Area of Expertise

Dr. Naik’s areas of expertise include:

  • Oncopathology: Special focus on the diagnosis and reporting of cancer, particularly in urothelial carcinoma.
  • Hematology: Proficient in peripheral blood smear (PBS) analysis, bone marrow aspiration and biopsy, cytochemistry, and flow cytometry for hematologic malignancies.
  • Histopathology: Skilled in grossing and reporting of surgical specimens, including small and large biopsies, and radical specimens. Expertise in immunohistochemistry for cancer diagnosis.
  • Cytopathology: Proficient in FNAC (Fine Needle Aspiration Cytology), fluid cytology, pap smears, and cell block preparation.
  • Clinical Pathology: Broad experience across various diagnostic pathology disciplines, offering comprehensive diagnostic services.

Research & Publications

Research Focus:

Dr. Naik’s research focuses on the molecular pathology of urothelial carcinoma, with particular emphasis on the diagnostic and prognostic utility of biomarkers like GATA-3.

Publications:

  • GATA-3 Expression in All Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma: Published in Indian Journal of Surgical Oncology in January 2020, this paper explores the role of GATA-3 as a biomarker in urothelial carcinoma.
  • Utility of GATA-3 in the Differential Diagnosis of Poorly Differentiated Urothelial Carcinoma: Accepted for publication in Journal of Cancer Research & Therapeutics in 2022, this research provides insights into using GATA-3 to differentiate poorly differentiated urothelial carcinoma from other malignancies.

Medical Breakthrough

Dr. Naik’s research on GATA-3 expression in urothelial carcinoma represents a significant advancement in the diagnostic accuracy for this type of cancer. The ability to differentiate poorly differentiated urothelial carcinoma using GATA-3 may improve both diagnosis and treatment planning for patients, allowing for better-targeted therapies.

Awards & Accolade

  • Dr. Naik has contributed to the field of pathology not only through her clinical work but also through her significant contributions to cancer diagnostics. Her published research has made an impact on improving the understanding and management of urothelial carcinoma.

Work Experience:

  • Assistant Professor, Department of Pathology, Government Medical College, Nanded: June 2022 – October 2022
  • Assistant Professor, Department of Pathology, Government Medical College, Miraj: October 2019 – May 2020
  • DNB Pathology Residency, Basavatarakam Indo-American Cancer Hospital & Research Centre, Hyderabad: May 2016 – May 2019